Akeso (AKESF) announced that its supplemental New Drug Application, sNDA, for gumokimab, AK111, has been accepted for review by the Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA. Active ankylosing spondylitis is the second indication for which gumokimab has gained acceptance for NDA review. The application for its use in treating moderate-to-severe psoriasis was previously accepted by the CDE in January 2025.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKESF: